What Will Hepion Pharmaceuticals Inc. (NASDAQ: HEPA) Be Like After It Drops -146.51% From Its Highs?

[view original post]

During the last session, Hepion Pharmaceuticals Inc. (NASDAQ:HEPA)’s traded shares were 0.59 million, with the beta value of the company hitting 1.38. At the end of the trading day, the stock’s price was $1.29, reflecting an intraday gain of 5.74% or $0.07. The 52-week high for the HEPA share is $3.18, that puts it down -146.51 from that peak though still a striking 10.85% gain since the share price plummeted to a 52-week low of $1.15. The company’s market capitalization is $97.63M, and the average intraday trading volume over the past 10 days was 1.01 million shares, and the average trade volume was 1.21 million shares over the past three months.

Hepion Pharmaceuticals Inc. (HEPA) received a consensus recommendation of a Buy from analysts. That translates to a mean rating of 2.00. HEPA has a Sell rating from 0 analyst(s) out of 1 analysts who have looked at this stock. 0 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 1 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be $0.

3 Tiny Stocks Primed to Explode The world’s greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We’ve set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free


Hepion Pharmaceuticals Inc. (HEPA) registered a 5.74% upside in the last session and has traded in the red over the past 5 sessions. The stock spiked 5.74% in intraday trading to $1.29 this Wednesday, 11/24/21, hitting a weekly high. The stock’s 5-day price performance is -6.52%, and it has moved by -13.42% in 30 days. Based on these gigs, the overall price performance for the year is -40.83%. The short interest in Hepion Pharmaceuticals Inc. (NASDAQ:HEPA) is 2.0 million shares and it means that shorts have 1.1 day(s) to cover.

The consensus price target of analysts on Wall Street is $5.00, which implies an increase of 74.2% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $5.00 and $5.00 respectively. As a result, HEPA is trading at a discount of -287.6% off the target high and -287.6% off the low.

An analysis of the company’s performance over the past 5 years shows that the company’s earnings grew an estimated 64.10%. While earnings are projected to return 65.60% in 2021.

HEPA Dividends

Hepion Pharmaceuticals Inc. is due to release its next quarterly earnings in December. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.

Hepion Pharmaceuticals Inc. (NASDAQ:HEPA)’s Major holders

Hepion Pharmaceuticals Inc. insiders own 0.14% of total outstanding shares while institutional holders control 21.54%, with the float percentage being 21.57%. Vanguard Group, Inc. (The) is the largest shareholder of the company, while 58 institutions own stock in it. As of Jun 29, 2021, the company held over 3.33 million shares (or 4.37% of all shares), a total value of $6.59 million in shares.

The next largest institutional holding, with 1.65 million shares, is of Blackrock Inc.’s that is approximately 2.16% of outstanding shares. At the market price on Jun 29, 2021, these shares were valued at $3.27 million.

>> 7 Top Picks for the Post-Pandemic Economy

Also, the Mutual Funds coming in first place with the largest holdings of Hepion Pharmaceuticals Inc. (HEPA) shares are Vanguard Total Stock Market Index Fund and Vanguard Extended Market Index Fund. Data provided on Jun 29, 2021 indicates that Vanguard Total Stock Market Index Fund owns about 2.07 million shares. This amounts to just over 2.71 percent of the company’s overall shares, with a $4.1 million market value. The same data shows that the other fund manager holds slightly less at 1.1 million, or about 1.44% of the stock, which is worth about $2.17 million.